{"id":2442,"date":"2025-01-15T16:01:43","date_gmt":"2025-01-15T13:01:43","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2442"},"modified":"2025-03-07T14:57:03","modified_gmt":"2025-03-07T11:57:03","slug":"3-drugs-receiving-accelerated-approval-from-the-fda-and-reviewed-by-the-office-of-inspector-general-raised-concerns","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/3-drugs-receiving-accelerated-approval-from-the-fda-and-reviewed-by-the-office-of-inspector-general-raised-concerns\/","title":{"rendered":"Trois m\u00e9dicaments b\u00e9n\u00e9ficiant d&#039;une approbation acc\u00e9l\u00e9r\u00e9e du FDA et examin\u00e9s par le Bureau de l&#039;inspecteur g\u00e9n\u00e9ral suscitent des inqui\u00e9tudes"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Malgr\u00e9 des preuves peu convaincantes et des divergences entre les \u00e9valuateurs, la Food and Drug Administration am\u00e9ricaine a rapidement approuv\u00e9 l&#039;Aduhelm de Biogen, le Exondys 51 (eteplirsen) de Sarepta et le Makena de Covis Pharma, a rapport\u00e9 mardi le Bureau de l&#039;inspecteur g\u00e9n\u00e9ral du minist\u00e8re de la Sant\u00e9 et des Services sociaux. L&#039;analyse a r\u00e9v\u00e9l\u00e9 que dans un cas, il n&#039;y avait aucune documentation sur des choix importants.<\/p>","protected":false},"excerpt":{"rendered":"<p>Malgr\u00e9 des preuves peu convaincantes et des divergences entre les \u00e9valuateurs, la Food and Drug Administration am\u00e9ricaine a rapidement approuv\u00e9 l&#039;Aduhelm de Biogen, le Exondys 51 (eteplirsen) de Sarepta et le Makena de Covis Pharma, a rapport\u00e9 mardi le Bureau de l&#039;inspecteur g\u00e9n\u00e9ral du minist\u00e8re de la Sant\u00e9 et des Services sociaux. L&#039;analyse a r\u00e9v\u00e9l\u00e9 que dans un cas, il n&#039;y avait aucune documentation sur des choix importants.<\/p>","protected":false},"author":1,"featured_media":2444,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[119,120,88,162,65],"class_list":["post-2442","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-eteplirsen","tag-exondys-51","tag-fda","tag-office-of-inspector-general","tag-sarepta"],"subtitle":"Selon un rapport des organismes de surveillance f\u00e9d\u00e9raux, les approbations de m\u00e9dicaments de Biogen Inc. et de Sarepta Therapeutics Inc. r\u00e9v\u00e8lent des probl\u00e8mes avec la proc\u00e9dure utilis\u00e9e par les r\u00e9gulateurs am\u00e9ricains des m\u00e9dicaments pour acc\u00e9l\u00e9rer l'autorisation des m\u00e9dicaments destin\u00e9s \u00e0 r\u00e9pondre \u00e0 des besoins non satisfaits.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/2442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=2442"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/2442\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/2444"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=2442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=2442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=2442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}